Health knowledge made personal
Join this community!
› Share page:
Search posts:

Beta-Amyloid PET Imaging Agents

Posted Jun 13 2010 5:00pm

Description of Invention:
Available for licensing and commercial development are two novel classes of compounds useful as radioligands for in vivo imaging of beta-amyloid peptides and plaques in humans.

diagram of radioligand structure

Beta-amyloid peptide deposition in the brain is a pathological feature of Alzheimer’s disease (AD). Early detection of beta-amyloid load in patients with suspected AD is vital to initiating early treatment, which can improve cognitive function and quality of life for many patients.

The invention describes novel derivatives of imidazopyridinylbenzeneamine (IMPY) and benzothizolylbenzeneamine (BTA), which demonstrate high in vitro binding affinity to human beta-amyloid. The difference between existing IMPY compounds and the novel derivatives is the substitution of an aryl halide with an aryl thioether group and replacement of a sulfur group of the pyridine ring with a nitrogen group. The new classes of compounds have the potential of providing improved amyloid imaging agents for Positron Emission Tomography (PET) with higher specificity for amyloid, low background noise, better entry into the brain and improved labeling efficiency.

In addition to the novel compounds, the invention also includes: 1) a new method of synthesizing the IMPY derivatives, using palladium as a catalyst, 2) methods of imaging beta-amyloid deposits in the brain by in vivo PET, magnetic resonance imaging (MRI) and other imaging methods involving the use of these compounds, and 3) and methods of labeling these compounds with radiotracers ([11-C] and [18-F]).

Lisheng Cai (NIMH)
Victor W Pike (NIMH)
Robert B Innis (NIMH)

Patent Status:
HHS, Reference No. E-156-2006/0
PCT, Application No. PCT/US2007/066939 filed 19 Apr 2007
US, Application No. 12/293,340 filed 17 Sep 2008

Relevant Publication:
  1. L Nichols, VW Pike, L Cai, RB Innis. "Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?" Biol Psychiatry. 2006 May 15;59(10):940-947. [ PubMed abs ]
  2. H Toyama et al. "PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease." Eur J Nucl Med Mol Imaging. 2005 May;32(5):593-600. [ PubMed abs ]
  3. L Cai et al. "Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease." J Med Chem. 2004 Apr 22;47(9):2208-2218. [ PubMed abs ]

Licensing Status:
Available for non-exclusive or exclusive licensing.

Collaborative Research Opportunity:
The NIMH Molecular Imaging Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Beta-Amyloid PET Imaging Agents. Please contact Suzanne Winfield at for more information.

Devices/Instrumentation - Diagnostics
Internal Medicine
Internal Medicine - Diagnostics
In-vitro Data

For Additional Information Please Contact:
Michael Shmilovich Esq.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5019
Fax: 301-402-0220

Ref No: 1359

Updated: 06/2010

Post a comment
Write a comment:

Related Searches